Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus IOPAMIDOL 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus IOPAMIDOL 250.
HYPAQUE-M,90% vs IOPAMIDOL-250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Iopamidol is a non-ionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. It acts by increasing the radiodensity of blood vessels and organs.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
1-2 mL/kg intravenously for contrast imaging, not to exceed 200 mL total; dose and rate vary by procedure and patient weight.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Terminal half-life 1.5-2 hours in normal renal function; may extend to 5-10 hours in severe renal impairment (CrCl <30 mL/min)
Renal: >95% unchanged; biliary/fecal: <5%
Renal: >90% unchanged via glomerular filtration; biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent